Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM)

Abstract

Serum cholinesterase (CHE) has been reported to be a significant indicator of liver function and prognosis in patients with cirrhosis. On the other hand, liver complications are frequent following allogeneic stem cell transplantation (HSCT). We therefore tested whether CHE was predictive of graft-versus-host disease and outcome in HSCT recipients. We studied 689 patients receiving a HSCT from an HLA-identical sibling (SIB) (n = 511), an alternative donor (n = 173) or a syngeneic twin (n = 5). Acute graft-versus-host disease (GVHD) was scored as 0–I, II, III–IV in 325 (47%), 279 (41%), and 85 patients (12%) respectively; 190 (28%) patients died of transplant-related complications (TRM). On day −7 the median CHE serum level was comparable in patients who either survived or died of TRM (5900 IU/l). On day 0, serum CHE levels were respectively 2310 and 2120 IU/l (P = NS) indicating the impact of the conditioning regimen. On day +7 after HSCT, the median level for surviving patients was 2598 IU/l vs 2309 IU/l for patients who subsequently died (P = 0.0002), on day +21 CHE levels were respectively 3348 vs 2528 IU/l (P < 0.00001), on day +50, 3575 vs 2358 IU/l (P < 0.00001) and on day +100 4193 vs 2729 IU/l (P < 0.00001). CHE levels on day +50 strongly correlated with aGVHD (3803 vs 3070 vs 1933 IU/l for patients with GVHD grade 0–I, II, and III–IV, respectively (P < 0.00001) and relapse (3569 for patients relapsing vs 3115 IU/l for patients not relapsing, P = 0.0006). In conclusion, (1) serum cholinesterase is a simple and reliable marker of acute GVHD and transplant-related complications; and (2) high CHE levels on day +50 predict relapse. If confirmed, the latter patients may be elegible for early reduction of immunosuppressive therapy.

Bone Marrow Transplantation (2001) 28, 1041–1045.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Heath DF . Organophosphorus poisons: anticholinesterases and related compounds. In: Heath DF (ed.). International Series of Monographs on Pure and Applied Biology Pergamon Press: New York, 1961 13: 8–20

    Google Scholar 

  2. Adler M, Verset D, Bouhdid H et al. Prognostic evaluation of patients with parenchymal cirrhosis: proposal of a new simple score J Hepatol 1997 26: 642–649

    Article  CAS  Google Scholar 

  3. Garello E, Battista S, Bar F et al. Evaluation of hepatic function in liver cirrosis: clinical utility of galactose elimination capacity, hepatic clarence of D-sorbitol and laboratory investigations Dig Dis And Sci 1999 44: 782–788

    Article  CAS  Google Scholar 

  4. Locasciulli A, Testa M, Valsecchi MG et al. On behalf of the Infectious Diseases Working Party of the European Blood and Marrow Transplantation Group. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the infectious disease Working Party of the European Blood and Marrow Transplantation Group Transplantation 1999 68: 1486–1491

    Article  CAS  Google Scholar 

  5. Bearman SI, Anderson GL, Mori M et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 1993 11: 1729–1736

    Article  CAS  Google Scholar 

  6. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of acute graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  Google Scholar 

  7. Bacigalupo A, Oneto R, Bruno B et al. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin Bone Marrow Transplant 1999 24: 653–659

    Article  CAS  Google Scholar 

  8. Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–462

    Article  Google Scholar 

  9. Dominietto A, Raiola AM, van Lint MT et al. Factors influencing hematologic recovery after allogeneic hemopoietic stem cells transplant (HSCT): graft-versus-host disease, donor type, cytomegalovirus infections and cell dose Br J Haematol 2001 112: 219–227

    Article  CAS  Google Scholar 

  10. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade Br J Haematol 1997 97: 855–864

    Article  CAS  Google Scholar 

  11. Atkinson K, Horowitz MM, Biggs JC et al. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers Bone Marrow Transplant 1988 3: 5–10

    CAS  PubMed  Google Scholar 

  12. Martin P, Nash R, Sanders J et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation Bone Marrow Transplant 1998 21: 273–279

    Article  CAS  Google Scholar 

  13. Bacigalupo A, Soracco M, Vassallo F et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation Bone Marrow Transplant 1997 19: 927–932

    Article  CAS  Google Scholar 

  14. Raiola AM, Van Lint MT, Lamparelli T et al. Toxicity and efficacy of 409 donor lymphocyte infusions for treatment of relapse after allogeneic bone marrow transplantation Bone Marrow Transplant 2001 27 (Suppl. 1): S127

    Google Scholar 

  15. Tsujikawa T, Uda K, Ihara T et al. Changes in serum diamine oxidase activity during chemotherapy in patients with hematological malignancies Cancer Lett 1999 147: 195–198

    Article  CAS  Google Scholar 

  16. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem cell transplantation New Engl J Med 2000 343: 750–758

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Associazione Italiana Ricerca contro il Cancro (AIRC) Milano grant to AB and Associazione Ricerca Trapianto Midollo Osseo (ARITMO) Genova. The great work of our nursing staff is gratefully acknowledged. The BMT transplant group from Hospital Gaslini, Genova Italy is also gratefully aknowledged.

Author information

Authors and Affiliations

Authors

Additional information

Unit of Clinical Epidemiology and Trials, National Institute for Cancer Research, Genova, Italy

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bacigalupo, A., Oneto, R., Bruno, B. et al. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM). Bone Marrow Transplant 28, 1041–1045 (2001). https://doi.org/10.1038/sj.bmt.1703281

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703281

Keywords

This article is cited by

Search

Quick links